Cross-country comparison in the evaluation of evolocumab by health technology assessment agencies in England, Canada, and Australia
Evolocumab is a proprotein convertase subtilisin/kexin type 9 inhibitor drug which has shown great treatment effects in the treatment of uncontrolled hypercholesterolemia, particularly elevated low-density lipoprotein cholesterol levels. Due to its significant costs, several health technology assess...
محفوظ في:
| المؤلفون الرئيسيون: | , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| سلاسل: | Heart and Mind |
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.heartmindjournal.org/article.asp?issn=2468-6476;year=2019;volume=3;issue=4;spage=140;epage=146;aulast=Varghese |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|